Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation

Molecular Cancer Therapeutics

Volumn 1, Issue 12, 2002, Pages 1139-1145

  Blanquicett, Carmelo ^a,e   Gillespie, G Yancey ^b   Nabors, L Burt ^c   Miller, C Ryan ^b,d   Bharara, Sumen ^b   Buchsbaum, Donald J ^d,e   Diasio, Robert B ^a,e   Johnson, Martin R ^a,e  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c The University of Alabama at Birmingham   (United States)

^d The University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOKINE; DEOXYCYTIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG DERIVATIVE; GAMMA INTERFERON; MESSENGER RNA; OXIDOREDUCTASE; RNA; THYMIDINE PHOSPHORYLASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; BRAIN; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; GLIOBLASTOMA; HUMAN; LIVER; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINES; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); GLIOBLASTOMA; HUMANS; INTERFERON TYPE II; LIVER; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OXIDOREDUCTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642517370     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Galanis, E., and Buckner, J. C. Chemotherapy of brain tumors. Curr. Opin. Neurol., 13: 619-625, 2000. (Pubitemid 32002642)
2. Macarthur, D. C., and Buxton, N. The management of brain tumours. J. R. Coll. Surg. Edinb., 46: 341-348, 2001. (Pubitemid 33133360)
3. Prados, M. D., and Levin, V. Biology and treatment of malignant glioma. Semin. Oncol., 27: 1-10, 2000. (Pubitemid 30390229)
4. Hildebrand, J., Sahmoud, T., Mignolet, F., Brucher, J. M., and Afra, D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology, 44: 1479-1483, 1994. (Pubitemid 24247441)
5. Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet, 345: 1008-1012, 1995.
6. Subach, B. R., Witham, T. F., Kondziolka, D., Lunsford, L. D., Bozik, M., and Schiff, D. Morbidity and survival after 1,3-bis(2-chloroethyl)-1- nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery (Baltimore), 45: 17-22; discussion 22-13, 1999.
7. Wang, M. L., Yung, W. K., Royce, M. E., Schomer, D. F., and Theriault, R. L. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am. J. Clin. Oncol., 24: 421-424, 2001. (Pubitemid 32730746)
8. Bajetta, E., Carnaghi, C., Somma, L., and Stampino, C. G. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori, 82: 450-452, 1996. (Pubitemid 27013326)
9. Budman, D. R., Meropol, N. J., Reigner, B., Creaven, P. J., Lichtman, S. M., Berghorn, E., Behr, J., Gordon, R. J., Osterwalder, B., and Griffin, T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol., 16: 1795-1802, 1998.
10. Ishikawa, T., Fukase, Y., Yamamoto, T., Sekiguchi, F., and Ishitsuka, H. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′- deoxy-5-fluorocytidine (capecitabine). Biol. Pharm. Bull., 21: 713-717, 1998. (Pubitemid 28374445)
11. Heggie, G. D., Sommadossi, J. P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987. (Pubitemid 17074634)
12. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Investig., 81: 47-51, 1988. (Pubitemid 18092231)
13. Ishikawa, T., Sekiguchi, F., Fukase, Y., Sawada, N., and Ishitsuka, H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res., 58: 685-690, 1998. (Pubitemid 28099478)
14. Tsukamoto, Y., Kato, Y., Ura, M., Horii, I., Ishitsuka, H., Kusuhara, H., and Sugiyama, Y. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm. Res., 18: 1190-1202, 2001. (Pubitemid 32900406)
15. Schuller, J., Cassidy, J., Dumont, E., Roos, B., Durston, S., Banken, L., Utoh, M., Mori, K., Weidekamm, E., and Reigner, B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol., 45: 291-297, 2000. (Pubitemid 30151522)
16. Nishimura, G., Terada, I., Kobayashi, T., Ninomiya, I., Kitagawa, H., Fushida, S., Fujimura, T., Kayahara, M., Shimizu, K., Ohta, T., and Miwa, K. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol. Rep., 9: 479-482, 2002.
17. Eda, H., Fujimoto, K., Watanabe, S., Ura, M., Hino, A., Tanaka, Y., Wada, K., and Ishitsuka, H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., 32: 333-338, 1993. (Pubitemid 23207988)
18. Sawada, N., Ishikawa, T., Fukase, Y., Nishida, M., Yoshikubo, T., and Ishitsuka, H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin. Cancer Res., 4: 1013-1019, 1998. (Pubitemid 28183404)
19. Endo, M., Shinbori, N., Fukase, Y., Sawada, N., Ishikawa, T., Ishitsuka, H., and Tanaka, Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int. J. Cancer, 83: 127-134, 1999. (Pubitemid 29409488)
20. Sawada, N., Ishikawa, T., Sekiguchi, F., Tanaka, Y., and Ishitsuka, H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res., 5: 2948-2953, 1999. (Pubitemid 29493974)
21. Blanquicett, C., Johnson, M., Heslin, M., and Diasio, R. B. Housekeeping gene (HKG) variability in normal and carcinomatous colorectal and liver tissues; applications in pharmacogenomic gene expression studies. Anal. Biochem., 303: 209-214, 2002. (Pubitemid 34407587)
22. Johnson, M. R., Wang, K., Smith, J. B., Heslin, M. J., and Diasio, R. B. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem., 278: 175-184, 2000. (Pubitemid 30090740)
23. Andratschke, N., Grosu, A. L., Molls, M., and Nieder, C. Perspectives in the treatment of malignant gliomas in adults. Anticancer Res., 21: 3541-3550, 2001. (Pubitemid 34224263)
24. Diasio, R. B., and Johnson, M. R. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology (Basel), 61: 199-203, 2000.
25. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000. (Pubitemid 30226214)
26. Johnson, M. R., Hageboutros, A., Wang, K., High, L., Smith, J. B., and Diasio, R. B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin. Cancer Res., 5: 2006-2011, 1999. (Pubitemid 29399251)
27. Mori, K., Hasegawa, M., Nishida, M., Toma, H., Fukuda, M., Kubota, T., Nagasue, N., Yamana, H., Hirakawa, Y. S. C. K., Ikeda, T., Takasaki, K., Oka, M., Kameyama, M., Toi, M., Fujii, H., Kitamura, M., Murai, M., Sasaki, H., Ozono, S., Makuuchi, H., Shimada, Y., Onishi, Y., Aoyagi, S., Mizutani, K., Ogawa, M., Nakao, A., Kinoshita, H., Tono, T., Imamoto, H., Nakashima, Y., and Manabe, T. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int. J. Oncol., 17: 33-38, 2000.
28. Wild-Bode, C., Weller, M., Rimmer, A., Dichgans, J., and Wick, W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res., 61: 2744-2750, 2001. (Pubitemid 32685864)
29. Goto, H., Kohno, K., Sone, S., Akiyama, S., Kuwano, M., and Ono, M. Interferon γ-dependent induction of thymidine phosphorylase/platelet- derived endothelial growth factor through gamma-activated sequence-like element in human macrophages. Cancer Res., 61: 469-473, 2001. (Pubitemid 32128599)
30. Knupfer, M. M., Poppenborg, H., Van Gool, S., Domula, M., and Wolff, J. E. Interferon-γ inhibits proliferation and adhesion of T98G human malignant glioma cells in vitro. Klin. Padiatr., 209: 271-274, 1997. (Pubitemid 27328980)
31. Dadie, B., Schartner, J., Vorpahl, J., and Preston, K. Interferon-γ induces apoptosis and augments the expression of Fas and Fas ligand by microglia in vitro. Exp. Neurol., 162: 290-296, 2000. (Pubitemid 30217724)
32. Mizutani, N., Fujikura, Y., Wang, Y. H., Tamechika, M., Tokuda, N., Sawada, T., and Fukumoto, T. Inflammatory and anti-inflammatory cytokines regulate the recovery from sublethal X irradiation in rat thymus. Radiat. Res., 157: 281-289, 2002. (Pubitemid 34263841)
33. Fujieda, S., Sunaga, H., Tsuzuki, H., Fan, G. K., and Saito, H. IL-10 expression is associated with the expression of platelet-derived endothelial growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett., 136: 1-9, 1999. (Pubitemid 29142295)
34. Denys, A., Udalova, I. A., Smith, C., Williams, L. M., Ciesielski, C. J., Campbells, A. J., Andrews, C., Kwaitkowski, D., and Foxwell, B. M. Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase of NF-κB in primary human macrophages. J. Immunol., 168: 4837-4845, 2002. (Pubitemid 34495944)
35. Pilkington, G. J. The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res., 17: 4103-4105, 1997. (Pubitemid 28017938)
36. Wilke, H. Future treatment options with Capecitabine in solid tumours. Eur. J. Cancer, 38: 21-25, 2002.